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A variety of clinical disorders result frommutations in
mitochondrial tRNA genes, leading to translational de-
fects. We show here that a protein complex from the
kinetoplastid protozoon Leishmania induces specific,
ATP-dependent import of human cytoplasmic tRNA1
Lys
into human mitochondria in vitro. The imported tRNA
undergoes efficient aminoacylationwithin the organelle
and supports organellar protein synthesis. Moreover,
translation in mitochondria from patients with my-
clonic epilepsy with ragged red fibers (MERRF) and
Kearns-Sayre syndrome (KSS), containing mutant
tRNALys genes, is stimulated to near-wild-type levels
and the formation of aberrant polypeptides sup-
pressed by complex-mediated import. These results
suggest a novel way to introduce RNAs for the modula-
tion of mitochondrial gene expression.
The mitochondrial genomes of a wide variety of protist,
plant, and animal species contain an insufficient number of
functional tRNA genes, and translation of mitochondrial
mRNAs is sustained by import of nucleus-encoded tRNAs (re-
viewed in Ref. 1). Although human mitochondria do not nor-
mally import tRNA, a number of neuromuscular degenerative
diseases are caused by mutations in mitochondrial tRNA genes
(2). For example, the genetic disease known as myoclonic epi-
lepsy with ragged red fibers (MERRF)1 is caused by the
A8344Gmutation in the mitochondrial tRNALys gene (3). Other
diseases such as the Kearns-Sayre syndrome (KSS) are char-
acterized by mitochondrial genomic deletions (4). Correction of
the tRNA defect may be possible by engineering the import
machinery derived from other species into human cells. Crude
extracts from yeast support the import of a yeast tRNA into
human mitochondria (5), and transfection of modified yeast
tRNA genes into cybrid cells rescues translation in, and activ-
ity of, MERRF-derived mitochondria (6), but the effect is only
partial, and there is considerable clonal heterogeneity.
An alternative approach is suggested by the observation that
certain yeast and human tRNAs, including human tRNA1
Lys are
imported into the mitochondria of the kinetoplastid protozoa
Trypanosoma (7) and Leishmania (8), indicating a broad spec-
ificity of the endogenous tRNA import machinery in these
organisms, which import a wide variety of tRNAs to support
mitochondrial translation in the complete absence of organellar
tRNA genes (9, 10). In Leishmania, short sequence motifs in
various tRNA domains are recognized as import signals (11).
A previously characterized motif YGGUAGAGC is present in
a number of kinetoplastid tRNAs, including Leishmania
tRNATyr(GUA), where it acts as an import signal (12). An
identical sequence is present in the D domain of human
tRNA1
Lys (Fig.1), explaining its recognition by the Leishmania
import apparatus.
Recently, we have isolated a large protein complex (the RNA
import complex or RIC) with an apparent molecular mass of
640 kDa from the inner membrane of Leishmania mitochon-
dria that induces the import of Leishmania tRNATyr into phos-
pholipid vesicles (13). This complex resolves into multiple pro-
tein species, including two, of apparent mass 45 and 21 kDa,
respectively, that bind to different tRNAs (tRNATyr and
tRNAIle) in an allosterically regulated manner (13). Thus, it
was of interest to determine whether RIC is capable of deliv-
ering tRNAs into the matrix of human mitochondria.
MATERIALS AND METHODS
Cell Culture and Preparation of Mitochondria—The hepatocellular
carcinoma cell line HepG2 was grown in RPMI 1640 medium supple-
mented with 10% fetal bovine serum. The following homoplasmic trans-
mitochondrial cybrids were derived by fusing mitochondria-less
143B206 cells with enucleated patient fibroblasts containing wild-type
or mutant mitochondria and cultivated in Dulbecco’s modified Eagle’s
medium (containing 4.5 g/liter glucose and 110 mg/liter sodium pyru-
vate) supplemented with 10% fetal bovine serum and 50 mg/liter uri-
dine: LB58, containing wild-type mitochondria (14); LB64, containing
MERRF mitochondria with the A8344G mutation in the mitochondrial
tRNALys gene (14); and FLP32.39, derived from a patient with the
Kearns-Sayre syndrome, harboring a 1902-bp mitochondrial DNA de-
letion between nucleotides 7846 and 9748 (15). Mitochondria were
isolated from cell lysates by differential centrifugation as described
(16). To prepare mitoplasts, the outer membrane was selectively re-
moved with 320 M digitonin (17).
Purification of RIC—Sodium deoxycholate extracts of Leishmania
tropica mitochondrial inner membranes were subjected to RNA affinity
chromatography and the 1 M Na eluate concentrated to yield RIC, as
described (13).
Import Substrates—Leishmania tRNATyr(GUA) and tRNAGln(CUG)
and 3-CCA terminated human cytoplasmic tRNA1
Lys(UUU) were pre-
pared by T7 RNA polymerase transcription of cloned or PCR-amplified
templates as described (8, 18). Lysylation of 32P-labeled tRNALys tran-
script was carried out as described (16), using a 0–80% ammonium
sulfate concentrated HepG2 cytosolic extract as the enzyme source.
Import Assay—Import into intact mitochondria or mitoplasts was
assayed by RNase protection as described previously (17). Briefly, mi-
toplasts (100 g of protein) were incubated with 32P-labeled RNA (2.5
nM) in the presence of 4 mM ATP and0.2 g of affinity-purified RIC at
37 °C for 15 min, then treated with RNases A plus T1, washed, and the
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RNase-resistant mitochondrial RNA recovered for gel electrophoretic
analysis. Intact mitochondria were preincubated for 1 h on ice before
the import incubation. Aminoacylated tRNAs were analyzed on 7 M
urea, 8% PAGE in 0.1 M sodium acetate, pH 5.0, at 4 °C and 7 V/cm,
with buffer recirculation (19).
In Organello Translation—Unless otherwise stated, mitoplasts or
mitochondria (100 g) were incubated for 1 h at 30 °C in 20 l of
translation mixture (0.25 M sucrose, 20 mM Tris-HCl, pH 7.5, 30 mM
KH2PO4, 5 mM sodium succinate, 50 mM KCl, 10 mM MgCl2, 10 mM
MgSO4, 12 mM creatine phosphate, 0.16 mg/ml creatine phosphokinase,
4 mM ATP, 0.5 mM GTP, 5 mM NADH, 2.5 mg/ml bovine serum albumin,
100 g/ml cycloheximide, 0.125 mM concentration each unlabeled amino
acid except methionine, 20 Ci of [35S]methionine (1000 Ci/mmol), 100
fmol of lysyl-tRNALys, and 280 ng of RIC. After washing the mitoplasts
with sucrose-Tris-EDTA buffer, [35S]methionine incorporation into pro-
tein was measured as hot trichloroacetic acid-precipitable counts/min
(20). Translation products were analyzed by 15–20% exponential gra-
dient SDS-PAGE (21) followed by fluorography.
RESULTS
Mitoplasts prepared from the human cell line HepG2 were
incubated with Leishmania tRNATyr and tested for import by
RNase protection. ATP- and RIC-dependent import was ob-
served (Fig. 1A). Import was tRNA-specific, since Leishmania
tRNAGln(CUG), which is not recognized by RIC (13), was not
imported (Fig. 1A). Moreover, import was sensitive to a range
of respiratory inhibitors (Fig. 1A), including m-chlorocarbonyl-
cyanide phenylhydrazine (CCCP, a protonophore), valinomycin
(a K ionophore), nigericin (a K/H exchanger), and oligomy-
cin (an inhibitor of F1F0 ATPase). CCCP disrupts transmem-
brane proton gradients, thus reducing the protonmotive force
that drives synthesis of ATP as well as various transport pro-
cesses across the inner mitochondrial membrane; valinomycin
neutralizes the electrical component of this gradient, while
nigericin equalizes the proton concentration across the mem-
brane without affecting the membrane potential; and oligomy-
cin blocks proton flow-through the F1F0 ATPase. Similar sen-
sitivities have been observed in the reconstituted phospholipid
vesicle system and reflect the intrinsic property of RIC as a
proton pump capable of generating a membrane potential at
the expense of ATP hydrolysis, as observed recently (22). Ap-
parently, hydrolysis of ATP generates a pH gradient that ac-
tually drives import (22). Significantly, human cytoplasmic
tRNALys was transferred to the matrix of HepG2 mitoplasts in
an RIC- and ATP-dependent manner (Fig. 1C), thus opening up
the possibility of modulating mitochondrial translation.
The RNA import complex was isolated from the inner mem-
brane and appears to work quite well when simply added to
phospholipid vesicles (13) or to human mitoplasts (Fig. 1) or to
RIC-depleted Leishmaniamitoplasts (data not shown). For suc-
cessful tRNA delivery, however, it is essential to reconstitute
intact mitochondria, i.e. organelles with an intact outer mem-
brane. When RIC was simply added to intact HepG2 mitochon-
dria and import incubations carried out without a preincuba-
tion step, little or no uptake of human cytoplasmic tRNALys
was observed (Fig. 1D). However, upon preincubation of intact
mitochondria with RIC for 60 min on ice, uptake was greatly
stimulated (Fig. 1D). A HepG2 cytosolic extract could not sub-
stitute for the preincubation (data not shown), and addition of
the extract to preincubated mitochondria did not have any
effect (Fig. 1D), indicating the lack of a requirement for cyto-
solic factors. The requirement of a preincubation step could be
due to some intrinsic feature of the composition or structure of
the outer membrane, such as the presence of sterols, resulting
in a slower rate of RIC insertion into the membrane.
To determine the intramitochondrial location of the tRNALys
after transfer through the outer membrane of preincubated
HepG2 mitochondria, postimport, RNase-treated mitochondria
were fractionated into outer membrane plus intermembrane
space and mitoplasts by treatment with digitonin, which selec-
tively solubilizes the outer membrane (17), and labeled tRNA
recovered from each fraction. At the concentration of digitonin
FIG. 1. RIC-induced import of tRNAs into human mitochon-
dria. A, import of Leishmania tRNATyr into HepG2 mitoplasts. The
complete system (lane 3) contained 100 fmol of 32P-labeled tRNATyr, 4
mM ATP, 0.2 g of RIC, and 100 g (as protein) of digitonin-resistant
mitoplasts. Lanes 1 and 2, ATP or RIC omitted, respectively. Lanes 4–7,
import assayed in the presence of CCCP, oligomycin, valinomycin plus
50 mM KCl, and nigericin, respectively (all inhibitors at 50 M). Lane 8,
Leishmania tRNAGln(CUG) replaced tRNATyr. Lane 9, input tRNATyr (2
fmol). B, cloverleaf structure of human cytoplasmic tRNALys(UUU). The
anticodon is underlined. C, upper, import of human cytoplasmic
tRNALys(UUU) into HepG2 mitoplasts in the presence of ATP and 0.2
g RIC (lane 2) or with RIC (lane 1) or ATP (lane 3) omitted; lower,
titration of RIC. D, import of human tRNALys into intact HepG2 mito-
chondria. Mitochondria were incubated with tRNA and ATP for 15 min
at 37 °C without (lanes 1 and 2) or after a preincubation for 60 min on
ice (lanes 3–6 and 8–10), before RNase treatment and recovery of
imported RNA. In lane 2, RIC (0.2 g) was added after addition of
import substrate, whereas in lanes 4, 6, and 8–10, RIC was present
during the preincubation. In lane 6, a concentrated HepG2 cytosolic
extract (10 g of protein) was present. Postimport, RNase-treated mi-
tochondria were treated with digitonin and the digitonin-soluble frac-
tion, representing the outer membrane plus intermembrane space (OM;
lane 8) was separated from the mitoplasts (MP; lanes 9 and 10), half of
which was treated with RNase (lane 10). Lanes 7 and 11, input tRNALys
(2 fmol). E and F, import of cytoplasmic tRNALys into mutant mitoplasts
(E) or mitochondria (F) derived from transmitochondrial cybrids LB64
(MERRF; lanes 1 and 2) or FLP32.39 (KSS; lanes 3 and 4) in the absence
(lanes 1 and 3) or presence (lanes 2 and 4) of RIC. In F, mitochondria
were preincubated with RIC as above. Lane 5, input tRNALys, 2 fmol.
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used (320 M), about 95% of the outer membrane marker kyn-
urenine hydroxylase, but less than 1% of the inner membrane
marker succinate deydrogenase was solubilized, as observed
previously (17), attesting to the specificity of the solubilization
procedure. About 40% of the internalized tRNA (i.e. resistant to
RNase treatment of the intact mitochondrion) was recovered
from the mitoplasts (Fig. 1D, lane 9) and the remainder from
the outer membrane-intermembrane space fraction (Fig. 1D,
lane 8). About 15% of the internalized tRNA was resistant to
RNase treatment of the recovered mitoplasts (Fig. 1D, lane 10);
this represents the tRNA in the matrix; the remainder is pre-
sumably stuck to the outer surface of the inner membrane and
therefore RNase-sensitive.
Next, we checked the ability of RIC to introduce cytoplasmic
tRNALys into mitochondria containing mutations in the or-
ganellar tRNALys gene and thus complement the translational
defects arising from such mutations. For this purpose, mito-
chondria were prepared from cybrid cell lines derived from
human patients with mitochondrially inherited genetic disor-
ders. Cybrid LB58 contains wild-type mitochondria (14). Cy-
brid LB64 is nearly homoplasmic for mitochondria derived
from a MERRF patient, which contain a single A-to-G transi-
tion in the mitochondrial tRNALys gene (14). Cybrid FLP32.39
is similarly derived from a patient with the Kearns-Sayre syn-
drome and is characterized by a 1.9-kb mitochondrial deletion
covering the tRNALys gene, as well as the COII, COIII, A6, and
A8 genes (15). RIC-induced import of cytoplasmic tRNALys into
LB64 and FLP32.39 mitoplasts (Fig. 1E) as well as preincu-
bated intact mitochondria (Fig. 1F) was observed.
We next determined the effect of aminoacylation of the cyto-
plasmic tRNALys on RIC-mediated import into human mito-
chondria. Indirect evidence indicates that aminoacylation is
not a requirement for import in kinetoplastid protozoa (23) but
appears to be necessary in yeast (24) and plants (25). The
CCA-terminated tRNA1
Lys transcript (Fig. 1) was lysylated in
vitro with an enzyme preparation from HepG2 cytosol, and the
charged and uncharged forms were resolved by electrophoresis
under acidic conditions (19). Nearly complete charging of the
transcript with lysine occurred, with the amino acid-RNA link-
age characteristically labile to heat at alkaline pH (Fig. 2A).
RIC-dependent import of both the charged and uncharged spe-
cies into HepG2 mitoplasts was observed, with about the same
efficiency (Fig. 2B). This experiment simultaneously shows
that import itself does not cause appreciable deacylation of the
tRNA (but see later).
Isoaccepting mitochondrial and cytosolic tRNAs may have
FIG. 2. RIC-induced import of charged and uncharged tRNA
into human mitochondria. A, lysylation of cytosolic tRNALys(UUU)
in vitro. 32P-Labeled tRNALys was incubated with crude human amino-
acyl-tRNA synthetase, unlabeled lysine, and ATP and the product re-
solved by acid gel electrophoresis. lane 1, enzyme omitted; lane 2,
complete system; lane 3, lysine omitted; lane 4, the product was deac-
ylated by heating at 65 °C for 10 min at pH 9. B, import into HepG2
mitoplasts of uncharged (lanes 1 and 2) or lysyl-tRNALys (lanes 3 and 4)
in the presence (lanes 1 and 3) or absence (lanes 2 and 4) of RIC. aa,
lysylated form; da, deacylated or uncharged form of tRNALys. C, ami-
noacylation status of imported tRNALys during translation in organello.
32P-Labeled lysyl-tRNALys was incubated with HepG2 mitoplasts in the
presence of a lysine-deficient amino acid mixture and RIC in the pres-
ence (lane 2) or absence (lane 3) of 100 g/ml chloramphenicol (CAM)
and the imported RNA analyzed by acid gel electrophoresis. D, amino-
acylation of cysolic tRNALys within human mitochondria. HepG2 mito-
plasts were incubated with RIC, lysine-deficient amino acid mixture,
and 32P-labeled tRNALys (lanes 3 and 4) or lysyl-tRNALys (lanes 5–7)
and the imported RNA analyzed as above. Lysine (0.125 mM) was added
before import incubation (lanes 4 and 6) or after 1 h of import incuba-
tion (lane 7) followed by 1 more h of incubation at 37 °C. Lanes 1 and 2,
input deacylated and acylated forms, respectively, of tRNALys.
FIG. 3. Rescue of mitochondrial translation by RIC-mediated
import. A, RIC- and lysyl-tRNALys-dependent translation in human
mitoplasts. HepG2 mitoplasts were incubated in translation mixture
containing cycloheximide, all amino acids (including [35S]methionine)
except lysine, and other components as indicated. Incorporation was
measured as hot trichloroacetic acid-precipitable counts/min. B, mito-
chondria from wild-type (LB58; lanes 1 and 2), MERRF (LB64, lanes 3
and 4), and KSS (FLP32.39; lanes 5 and 6) were incubated in the
presence of a complete amino acid mixture (including lysine) and cyclo-
heximide and translation products analyzed by SDS-PAGE. In lane 2,
chloramphenicol was added. Lanes 3–6 contained lysyl-tRNALys. RIC
was present in lanes 4 and 6. Radiolabeled mitochondria-encoded pro-
teins are indicated at the left. CYB, apocytochrome b; M1 and M2,
aberrant translation products.
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considerable structural differences, and it is by no means cer-
tain that an imported cytosolic species would be recognized by
the prokaryotic-type organellar ribosome or by the mitochon-
drial aminoacyl-tRNA synthetase. To test the ability of im-
ported cytosolic tRNALys to support mitochondrial translation,
HepG2 mitoplasts were incubated in the presence of cyclohex-
imide (to block residual cytoplasmic translation) under lysine-
limiting conditions with RIC, ATP, and lysyl-tRNALys; RIC-
mediated delivery of the charged tRNA should then rescue
organellar protein synthesis. The mitoplasts used were of
greater than 95% purity, as shown by marker assays (see
above), and by the lack of significant cycloheximide-sensitive
amino acid incorporation due to the near-complete solubiliza-
tion of the outer membrane and any associated cytoplasmic
polysomes by digitonin treatment. As shown in Fig. 3A, left
panel, in the presence of RIC, lysyl-tRNALys, but not the un-
charged species, could partially replace lysine for chloramphen-
icol-sensitive protein synthesis in lysine-deficient mitoplasts.
Lysyl-tRNA-dependent translation was competed out by excess
Leishmania tRNATyr, indicating the involvement of the RIC
tRNA import pathway, whereas lysine-dependent translation,
presumably involving an inner membrane amino acid carrier,
was not (Fig. 3A, right panel). There was no detectable deacyl-
ation of lysyl-tRNALys imported alone in the presence of RIC
(Fig. 2B). However, in the presence of a lysine-deficient amino
acid mixture, the imported tRNALys underwent deacylation,
and deacylation was inhibited by chloramphenicol (Fig. 2C),
indicating the direct transfer of lysine from the imported tRNA
to the elongating polypeptide chains. These results argue
against the possibility that free lysine, generated by deacyla-
tion of the cytoplasmic tRNA before or during import, was
responsible for the observed effects. Additionally, about 75% of
tRNALys underwent acylation within the mitochondrion in the
presence of lysine (Fig. 2D, lanes 3 and 4), and imported lysyl-
tRNALys, which underwent deacylation in the presence of a
lysine-deficient translation mixture (Fig. 2D, lane 5), became
reacylated on addition of lysine added simultaneously (Fig. 2D,
lane 6) or subsequently (Fig. 2D, lane 7). Thus, the cytoplasmic
tRNALys is recognized by the mitochondrial lysyl-tRNA synthe-
tase, as observed previously (26), and undergoes multiple
rounds of decylation and reacylation during translation within
the organelle.
The mutant mitochondria exhibited qualitative as well as
quantitative defects of translation. In in organello translation
assays, a variable degree of inhibition of individual translation
products was observed with LB64 mitochondria, ranging from
4.5% of the wild-type level for ND5 to 56.7% for ND3 (Fig. 3B,
lane 3); the overall decline in translation rate was about 75%.
Moreover, aberrant translation products of 47 and 34 kDa were
present. These results are consistent with those obtained with
intact cells (14), except that the two smallest aberrant products
observed in that study were not clearly apparent. FLP32.39
mitochondria were completely defective for synthesis of all
polypeptides except for ND4L, which was reduced to 22% of the
wild-type level (Fig. 3B, lane 5). In the presence of RIC and
cytoplasmic lysyl-tRNALys, the translation of individual
polypeptides was significantly stimulated to 35–100% of wild-
type levels in both of the mutants (Fig. 3B, lanes 4 and 6).
Under these conditions, the aberrant products of LB64 mito-
chondria disappeared. In RIC-treated FLP32.39 mitochondria,
COII, COIII, A6, A6, and A8 were missing due to deletion of
the corresponding genes, but unexpectedly, ND1 was also ab-
sent, being replaced by a slightly larger polypeptide (Fig. 3B,
lane 6). The reason for this is unknown; it may be due to
translational read-through caused by a previously undetected
frameshifting mutation in the ND1 gene.
DISCUSSION
The A8344G mutation in the mitochondrial tRNALys gene of
MERRF patients causes severe translational defects through
inefficient aminoacylation of the mutant tRNA (27) and/or in-
effective codon recognition (28). The system of translational
correction described above exploits the broad specificity of the
protozoal RNA import complex to introduce a human cytosolic
tRNA into human mitochondria. The imported tRNA is highly
efficient in translational rescue; the small fraction of the tRNA
transferred to the matrix (Fig. 1) suffices to restore translation
to nearly wild-type levels, as well as to suppress aberrant
polypeptide formation (Fig. 3). This may be due to the high
level of aminoacylation of the imported tRNA within the or-
ganelle and direct transfer of the lysine to the translating
ribosome (Fig. 2). In contrast, yeast tRNA derivatives are ami-
noacylated with variable efficiency within human mitochon-
dria, and this, together with variable expression levels, may
account for the observed clonal heterogeneity (6).
Traditionally, it has been difficult to introduce exogenous
nucleic acids into mitochondria. The RIC is a molecular ma-
chine that easily inserts into membranes in a defined orienta-
tion (22) and is active through double membranes, enabling
transfer into the matrix of intact mitochondria (Fig. 1). The
issue of membrane permeability of this large complex is inter-
esting and needs further mechanistic studies.
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